Cellectar Biosciences, Inc. — 2012 Q3 Form 10-Q
Issuer and period: The supplied filing identifies the registrant as Novelos Therapeutics, Inc. (the company resulting from its 2011 reverse acquisition of Cellectar, Inc.); it covers the quarter and nine months ended September 30, 2012. The company was a development-stage cancer drug developer with no product revenue.
Financial performance and position
- Q3 2012: Operating expenses and operating loss were $2.054 million, versus $1.911 million a year earlier. Net loss was $2.052 million, compared with $1.909 million; a $543,359 deemed dividend from extending warrant terms increased the loss attributable to common stockholders to $2.596 million, or $0.06 per share, versus $1.909 million, or $0.07 per share.
- Nine months: Operating expenses and operating loss were $6.592 million, versus $5.019 million in 2011. Net loss was $6.640 million, versus $5.470 million; including the $543,359 deemed dividend, loss attributable to common stockholders was $7.183 million, or $0.18 per share, versus $5.470 million, or $0.25 per share.
- Expense trends: Nine-month R&D expense rose 59% to $3.896 million, mainly as clinical trials and manufacturing activity resumed or expanded. G&A rose 47% to $2.696 million, principally from staffing, stock compensation, investor relations and public-company costs. No revenue or gross margin was reported.
- Cash flow and liquidity: Cash and cash equivalents were $5.598 million at September 30, versus $5.506 million at year-end 2011. Operating activities used $4.891 million over nine months; financing provided $5.020 million, chiefly from the June offering. The company reported $5.598 million in total current assets and $736,792 in current liabilities.
- Debt and equity: Total liabilities were $1.322 million, including $450,000 in long-term notes payable and approximately $4,665 in capital lease obligations. Stockholders’ equity was $9.067 million. Common shares outstanding were 43.460 million at quarter-end and 46.398 million as of November 2, 2012.
Material changes and developments
- Research and development spending increased as the company advanced LIGHT imaging trials and the HOT radiotherapeutic Phase 1b trial. The company also increased hiring and manufacturing support.
- G&A was lower in Q3 year over year, partly because a $125,000 directors’ and officers’ insurance reimbursement reduced legal expense. Nine-month G&A nevertheless increased substantially versus 2011.
- In June 2012, the company raised $4.871 million net in a public offering. In September it extended the expiration of certain $1.00 Class B warrants; that modification generated the $543,359 deemed dividend. In October, holders exercised warrants for $937,500, while warrants to purchase 4.318 million shares expired unexercised.
- On November 2, 2012, the company raised $2.0 million gross in a private placement of stock and warrants, designated for a LIGHT clinical-stage manufacturing facility. The filing estimated the facility would cost about $3.0 million and take about one year to complete; vendor commitments had not yet been made.
Outlook, risks and contingencies
- Management expected ongoing operating losses and stated that cash on hand plus October warrant proceeds would fund operations at budgeted levels through May 2013. The November placement was designated for the facility, and the filing said additional financing would be needed to execute the operating plan beyond May 2013. There is no assurance funding will be available on acceptable terms.
- The company’s pipeline included LIGHT (I-124-CLR1404), with Phase 1–2 imaging trials ongoing across 11 solid-tumor indications; HOT (I-131-CLR1404), in a Phase 1b dose-escalation trial; and preclinical GLOW2. Management anticipated HOT Phase 2 trials in Q3 2013 and a GLOW2 IND submission in the second half of 2013, subject to funding. These were forward-looking plans, not assured milestones.
- The filing identifies clinical, regulatory, manufacturing, financing, competition and dilution risks. The company had an accumulated deficit of $38.120 million and warned that inadequate funding could delay, scale back or end programs. It had suspended development of legacy NOV-002 and NOV-205.
- A securities class action was dismissed with prejudice and the appeal deadline passed without an appeal. A separate dispute with ZAO BAM remained on appeal; management did not expect litigation contingencies to materially affect financial position, results or cash flows.
- Management reported disclosure controls and procedures were effective as of September 30, 2012 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Novelos Therapeutics, Inc., despite the request metadata naming Cellectar Biosciences, Inc.
- Assess cash burn, the stated May 2013 runway, and the availability and terms of financing needed beyond that date.
- Track clinical-trial progress and funding dependencies for LIGHT, HOT and GLOW2, as well as the timing and full funding of the proposed manufacturing facility.
- Review the share and warrant counts after the November placement and October warrant exercises and expirations, including potential dilution from outstanding securities.
- Monitor the ZAO BAM appeal and confirm whether any further developments affect the company’s contingencies.